Supplementary Materials



Figure S1. Scheme of radiolabeling procedure and the characterization of ^{111}In-DOTA-anti-OX40 mAb.

Table S1. Biodistribution results of ^{111}In-DOTA-anti-OX40 mAb obtained from mice with bilateral CT26 tumors.

	Control	Curcumin	RT	COMB
Heart	0.43 ± 0.06	0.73 ± 0.32	0.71 ± 0.04	0.93 ± 0.48
Lung	0.80 ± 0.09	1.46 ± 0.16	1.11 ± 0.16	2.00 ± 0.60
Liver	1.09 ± 0.40	1.92 ± 1.19	2.07 ± 1.88	3.48 ± 1.88
Spleen	1.91 ± 0.34	3.93 ± 1.02	3.52 ± 0.15	3.58 ± 0.58
Pancreas	0.51 ± 0.25	0.79 ± 0.41	0.88 ± 0.39	0.98 ± 0.45
Kidney	1.05 ± 0.15	1.84 ± 0.46	1.23 ± 0.13	1.81 ± 0.71
Stomach	0.37 ± 0.11	0.63 ± 0.16	0.55 ± 0.22	0.89 ± 0.34
Small Intestine	1.28 ± 0.26	1.35 ± 0.13	1.78 ± 0.98	2.80 ± 0.49
Large Intestine	0.31 ± 0.07	0.54 ± 0.20	0.65 ± 0.39	0.80 ± 0.21
Blood	2.46 ± 0.27	5.21 ± 4.73	3.27 ± 0.56	4.95 ± 2.16
Bone	0.13 ± 0.06	0.24 ± 0.06	0.14 ± 0.06	0.42 ± 0.30
Muscle	0.28 ± 0.08	0.40 ± 0.09	0.43 ± 0.14	0.60 ± 0.33
Primary tumor	0.88 ± 0.26	1.96 ± 1.19	1.24 ± 0.09	2.88 ± 0.98
Secondary tumor	0.79 ± 0.22	1.65 ± 0.58	1.25 ± 0.04	3.04 ± 0.80

Numbers represent mean values in %ID/g from three mice in each group.